Alliance Pharma plc announced earnings guidance for the year ended December 31, 2012. For the year turnover was expected to be £44.9 million against £46.0 million a year ago. There was a record increase of £1.1 million in HydromolTM sales, taking the sales for 2012 to £4.7 million, representing growth of 29% over the previous year.

As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations.